

## Board Meeting in Public Tuesday, 26 September 2023

<b>Title of Report</b>	Care Quality Commission (CQC) Action Plan Report	<b>Agenda No.</b>	3.4
<b>Nature of Report</b> (tick one)	<input checked="" type="checkbox"/> Official	<input type="checkbox"/> Official Sensitive	
<b>Author(s)</b>	Iroro Agba, Assistant Director of Quality		
<b>Lead Executive</b>	Helen Gillan, Director of Quality		
<b>Non-Executive Director Sponsor</b> (if applicable)	N/A		
<b>Presented for</b> (tick all that applies)	<input checked="" type="checkbox"/> Approval	<input type="checkbox"/> Information	<input checked="" type="checkbox"/> Update
<b>Purpose of the report and key issues</b>			
<p>The purpose of this paper is to provide an update and assurance to the Board on NHSBT's progress against its CQC action plan, following the Well-Led and regulated activity inspections in June &amp; August 2022.</p> <p>An existing MUST action pertaining to Regulation 17: Good Governance has been split into two (2): Board to complete expert-led training on anti-racism – Complete. Board to complete coaching workshop on anti-racism – Target date November 2023.</p> <p>Of the 33 actions raised to address the 6 MUST (Well-Led) findings, 30 have been closed in total (1 more since the last update to the Board).</p> <p>Whilst ongoing work continues by our IT team and Freedom to Speak Up (FTSU) Guardian to explore an alternative mobile reporting tool, a 'do nothing' option may emerge as the preferred choice, considering existing measures within NHSBT.</p> <p>Therapeutic Apheresis Service (TAS) have completed the strategic outline case (SOC) for the procurement of a digital solution for its data and information management. It is expected to be reviewed by NHSBT's investment committee (IC) in September 2023, which has resulted in a delay to close this action.</p>			
<b>Previously Considered by</b>			
The action plan is considered by the Executive Team on a fortnightly basis.			
<b>Recommendation</b>	The Board is asked to approve an extension request for: 1) The review of TAS SOC to 30 <sup>th</sup> September 2024.		
<b>Risk(s) identified (Link to Board Assurance Framework Risks)</b>			
BAF 09: Regulatory risk			

## Blood and Transplant

<b>Strategic Objective(s) this paper relates to:</b> [Click on all that applies]		
<input type="checkbox"/> Collaborate with partners	<input checked="" type="checkbox"/> Invest in people and culture	<input type="checkbox"/> Drive innovation
<input type="checkbox"/> Modernise our operations	<input type="checkbox"/> Grow and diversify our donor base	
<b>Appendices:</b>	CQC Report Action Plans	
	<ol style="list-style-type: none"><li>1. Well Led Action Plan</li><li>2. Blood Donation Action Plan</li><li>3. Therapeutic Apheresis Services Action Plan</li></ol>	